Analyst consensus rating
Tvardi Therapeutics Analyst Rating: Buy
TVRD is rated Buy by 8 analysts with a $8.50 target. As of 2026-08-29.
Direct answer
Tvardi Therapeutics's consensus rating is Buy.
8 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $8.50.
Forecast evidence checked August 29, 2026.
Get free Tvardi Therapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $1.82
- Average price target
- $8.50
- High price target
- $13.00
- Low price target
- $3.00
- Low target gap
- +64.8%
- Target upside
- +367%
- High target gap
- +614.3%
- Target range width
- 549.5%
- Consensus rating
- Buy
- Analysts
- 8
- Evidence date
- August 29, 2026
- Valid through
- September 5, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Tvardi Therapeutics?
Tvardi Therapeutics has a verified Buy consensus. The same dataset has an average price target of $8.50.
How far are Tvardi Therapeutics's low and high targets from the recorded price?
The low target implies +64.8%, while the high target implies +614.3%.
How many analysts are included in Tvardi Therapeutics's consensus?
The verified consensus includes 8 analysts.
How is Tvardi Therapeutics's target upside or downside calculated?
The average target of $8.50 is divided by the recorded price of $1.82, then one is subtracted to produce +367%. This does not guarantee a future return.
When was Tvardi Therapeutics's analyst forecast verified?
The data was verified on 2026-08-29. The dataset is valid through 2026-09-05.